Transfer of urine samples to Thermo Fisher
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your VRCI notes
Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces it has completed successful transfer of a portion of the Company's urine samples as announced as part of the global commercialisation and licensing agreement announced in November 20231. As previously stated, it demonstrates the additional value in the Company's data and sample assets for research.
Sara Barrington, CEO, said:
"We are delighted to announce the successful completion of this transfer, within the agreed timeline. This achievement not only highlights our commitment to delivering on our agreements, but also underscores the substantial value inherent in the Company's data and sample assets for research purposes."
- Please refer to RNS number 4652T for further information. A copy of this announcement can also be found on the company website https://verici-dx-plc.flint-platform.com/regulatory-news/44270
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.